Study Exclusion reasons Remarks Reference(s)
Gilboa, 2021 -

Gilboa M J Infect Dis 2021 Nov 29;jiab584. 10.1093/infdis/jiab584

Danza, 2022 case series no control group Omicron became the predominant SARS-CoV-2 variant in LAC during the week ending December 18, accounting for 57% of all sequenced specimens;Omicron prevalence continued to increase, accounting for 99% of all sequenced specimens for the week ending January 8, 2022

Danza P et al. MMWR Morb Mortal Wkly Rep 10.15585/mmwr.mm7105e1

COV-BOOST, 2021 randomized controlled trial no clinically relevant endpoint Phase 2 trial.

Munro APS Lancet 2021 Dec 2;S0140-6736(21)02717-3. 10.1016/S0140-6736(21)02717-3

Mattiuzzi, 2022 - other same population alder study than mattiuzzi, 2022

Mattiuzzi C Eur Geriatr Med 2022 Jan 24. 10.1007/s41999-022-00615-7